Evaluating only Cue Health’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Founder chaos.
Key Events Timeline
FOUNDING
Cue Health founded
LAYOFF
Market downturn forces cuts
REGULATORY ACTION
FDA grants Cue Health Emergency Use Authorization for its at-home COVID-19 molecular test. Cue secures contracts with the NFL, NBA, US military, and CDC for large-scale COVID testing operations. SoftBank Vision Fund leads $235M funding round. The company rapidly scales to 600+ employees and seven testing labs nationwide. Revenue reaches approximately $350M in 2021.
DOWN ROUND
COVID testing demand begins collapsing globally as vaccination rates rise, Omicron variant produces milder illness, and testing fatigue sets in. Cue's revenue falls approximately 97% from 2021 levels in the first half of 2022. The company cannot pivot rapidly enough to sustain its 600-person workforce and multi-site laboratory infrastructure against near-zero demand.
SHUTDOWN
July 22, 2022: Cue Health suddenly ceases all operations with approximately 600 employees, providing minimal advance notice to staff. Total funding of $430M consumed. December 2022: The FDA recalls Cue's COVID-19 test citing a higher-than-acceptable false negative rate — retroactively invalidating the product that the company's entire COVID-era operations were built upon and adding a product failure epilogue to the runway-zero shutdown.
SHUTDOWN
Bankruptcy: Cue Health ceases operations
Full Analysis
Free · no account needed
Documented cause
Cue Health was founded in 2010 in San Diego by Ayub Khattak (CEO) and Clint Sever as a molecular diagnostics company. For its first decade, the company operated relatively quietly, developing portable diagnostic technology. The COVID-19 pandemic transformed the company's trajectory: Cue developed an at-home COVID-19 PCR test and received Emergency Use Authorization from the US FDA in August 2020. The company secured contracts with the NFL, NBA, the US military, and the CDC to provide COVID testing at scale. Cue raised approximately $430 million from a roster of blue-chip investors: SoftBank Vision Fund ($235 million), Danaher, Foresite Capital, and others. The company operated seven testing labs across the United States and expanded to over 600 employees. Revenue in 2021 was approximately $350 million. Then, in the course of 2022, COVID testing demand fell off a cliff as vaccination rates rose, infection severity declined, and testing fatigue set in. Cue's revenue dropped approximately 97% from 2021 levels in the first half of 2022. On July 22, 2022, Cue Health suddenly ceased operations with nearly 600 employees, announcing the shutdown with minimal advance notice. In December 2022, the FDA recalled Cue's COVID test due to concerns about accuracy, specifically that the test had a higher-than-expected false negative rate — a devastating retroactive invalidation of the product that the company had built its emergency-scale operations on.
Lesson
“Emergency Use Authorization is not product validation — it is an expedited regulatory pathway for crisis conditions that does not survive the crisis. A business built around a single emergency-authorized product in a single emergency market has zero business model the day the emergency ends. The 97% revenue decline in six months was not a risk scenario: it was the inevitable baseline outcome.”
Failure anatomy
Collapse type
Sudden Collapse
⚡ HIGH
Hype cycle
covid diagnostics boom
Moat type
None
Fatal mistake
Single Product Entirely Dependent on COVID Emergency Demand